Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

Trial Profile

Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs SAR 100842 (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Jun 2017 Results assessing the identification of a transcriptomic signature correlated with modified rodnan skin score (Mrss), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 24 Mar 2016 Extension part is now incorporated in this study thus changes in official title, purpose, design, treatment as per ClinicalTrials.gov record.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top